CITY OF INDUSTRY, Calif., July 28, 2005 (PRIMEZONE) -- U.S. BioDefense, Inc. (OTCBB:UBDE) announced today that it has recently sponsored the successful launch of 1-800-STEM-CELLS.COM, a major success for the Stem Cell Industry Council, a newly formed IRS approved 501C3 Non-Profit Organization "Advocating Stem Cell Education, Research, and Fundraising".
1-800-STEM-CELLS.COM is part of an ongoing campaign to accelerate the awareness of Cord Blood Banking and the advancement of Stem Cell research and to connect patients with physicians. In addition, 1-800-STEM-CELLS.COM will be a center for information on the latest technology and treatments including the growing importance of Cord Blood Banking. Cord blood is a valuable source of stem cells, which are genetically unique to your baby and family. Cord blood, which is also called "placental blood," is the blood that remains in the umbilical cord and placenta following birth and after the cord is cut. 1-800-STEM-CELLS.COM provides connections to leading Cancer treatment and regenerative therapy centers at hospitals and research labs in the United States and Internationally.
"We are excited to be part of the effort to bring patients, doctors and the most recent stem cell technology together," said David Chin, CEO of U.S. BioDefense. We urge all medical professional to join the stem cell industry council and to participate in our upcoming Sponsorship of the Stem Cell Industry Council's Sports, Stars and Car Gala for the benefit of Stem Cell Research on October 15."
About the Stem Cell Industry Council
The Stem Cell Industry Council, Inc. is a non profit organization consisting of a consortium of industry members for advancing the Stem Cell Industry. All membership donations to Stem Cell Industry Council, Inc. are tax-deductible under the Internal Revenue Code of the Internal Revenue Service for computing income and estate taxes. The 1-800-STEM-CELLS Web Site and Toll Free Directory is a program of Stem Cell Industry Council, Inc., a federally recognized 501(c)(3) non-profit, tax-exempt organization (Tax Exempt ID# 20-2066901) incorporated with the California Department of Corporations by Freeman Freeman & Smiley on December 28, 2004. The IRS has issued a determination letter to this effect.
About 1-800-STEM-CELLS
1-800-STEM-CELLS(r) is the trusted toll free and online resource for connecting Patients with Physicians.
1-800-STEM-CELLS(r) is the No. 1 directory service to help your family contact local physicians, cord blood banks, and oncologists. We provide connections to leading Cancer treatment and regenerative therapy centers at hospitals and research labs in the United States and Internationally. Stem cells are used in transplant medicine to regenerate a patient's blood and immune system after they have been treated with chemotherapy and/or radiation to destroy cancer cells. The ability of cord blood stem cells to differentiate, or change into other types of cells in the body is a new discovery that holds significant promise for improving the treatment of some of the most common afflictions such as Diabetes, Paralysis, Battens Disease, Heart Disease, Stroke, and Alzheimer's.
About U.S. BioDefense, Inc.
U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology. U.S. BioDefense, Inc. is focused on transferring, researching, and commercializing groundbreaking technology from Universities, Research Labs, Fortune 500 Companies, and Government Agencies. U.S. BioDefense has formed SCRI, Stem Cell Research Institute, The company is aggressively developing its intellectual property and product portfolio through signing current and negotiating ongoing commercial evaluation agreements and option to exclusively and/ or non exclusively license agreements. Below are five new U.S and Worldwide Patent and Patent Pending Stem Cell technology breakthroughs:
1)Generation of Human Neural Crest Stem Cell Line and Its Utilization
in Human transplantation;
a)University of British Columbia; World Patent Number WO 03/054202
(i)Used to treat and hopefully cure brain and spinal cord
injuries.
2) Method for Selective Engraftment of Drug-Resistant Hematopoietic
Stem Cells
a) University of Minnesota; US Patent Number 6,485,722
(i) Improves Cancer Therapy and selective engraftment of
transfused or transplanted tissues.
1. Method that transfers drug resistance genes into normally
drug sensitive cells.
(ii) Present method thus allows the administration of higher
dosage of chemotherapeutic agents to the host.
3)Liver Cell Progenitor and Use for Treatment of Liver Diseases
a) Biomedica U of London; World Patent Number WO 03/006638
(i) Repopulation of the liver with healthy cells for patients
with liver disease
(ii) Allow the development of an "artificial liver".
4) Isolation and Characterization of a Human Oral Keratinocyte;
(a) University of Michigan; Pending
(i) Major reconstructive surgery
(ii) Help with chronic conditions such as diabetes or systemic
illnesses like diabetes or hemophilia.
1. Infuse the piece of tissue with gene therapy compounds
5) Use of Non-marrow Stem Cells for Cardiac Regeneration;
a) University of Texas MD Anderson Cancer Center; Patent Pending
(i) Method for treating damaged myocardium
(ii) Circumventing the pain and anesthesia complications associated
with bone marrow procedures.
Allows individual to serve as his or her own source of donor cells
U.S. BioDefense is forming a Stem Cell Center of Excellence consisting of Medical Advisors to transfer, research, develop, fund, and commercialize technology in California and has submitted applications for several major Grants provided by the United States Department of Defense's Chemical Biological Defense Agency and the National Institute of Health. Please visit the company's web site for more information and for a white paper on Stem Cell technology transfer, analyzing California university and industry participants' intellectual property resources including ViaCell (Nasdaq:VIAC), Aastrom Biosciences (Nasdaq:ASTM) and StemCells, Inc. (Nasdaq:STEM).